A phase I, first-in-human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937.

Benn, Paul D; Zhang, Ying; Kahl, Lesley; Greene, Thomas J; Bainbridge, Veronica; Fishman, Cindy; Wen, Bo; Gartland, Martin

Benn, Paul D; Zhang, Ying; Kahl, Lesley; Greene, Thomas J; Bainbridge, Veronica; Fishman, Cindy; Wen, Bo; Gartland, Martin.

Affiliation

Benn PD; ViiV Healthcare, Brentford, UK.
Zhang Y; GSK, Collegeville, Pennsylvania, USA.
Kahl L; ViiV Healthcare, Brentford, UK.
Greene TJ; GSK, Collegeville, Pennsylvania, USA.
Bainbridge V; GSK, Brentford, UK.
Fishman C; GSK, Collegeville, Pennsylvania, USA.
Wen B; GSK, Collegeville, Pennsylvania, USA.
Gartland M; ViiV Healthcare, Durham, North Carolina, USA.

Pharmacol Res Perspect ; 11(3): e01093, 2023 06.

Article in En | MEDLINE | ID: mdl-37269076

Subject(s)

Powders; Humans; Administration, Oral; Biological Availability; Area Under Curve; Tablets

Key words

HIV-1 maturation inhibitor; bioavailability; dose escalation; first-in-human; food effect

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Powders Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Pharmacol Res Perspect Year: 2023 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google